|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01877 JUNSHI BIO
Nominal 
21.900 +0.140 (+0.643%) | 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 2,498,420 | 28.235% | 1,948,317 | 1,502,550 | 1,453,493 | 4,024,841 |
| Cost of Sales | (522,756) | 4.790% | (498,861) | (667,290) | (526,282) | (1,258,187) |
| Gross Profit | 1,975,664 | 36.304% | 1,449,456 | 835,260 | 927,211 | 2,766,654 |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | 3,359 | -82.972% | 19,726 | (23,484) | (47) | 342 | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (116,102) | 231.474% | (35,026) | (60,484) | (71,032) | (48,463) | |
| Profit / (Loss) before Taxation | (986,574) | -27.406% | (1,359,028) | (2,489,887) | (2,675,202) | (592,648) | |
| Taxation | 13,881 | -- | (22,552) | (43,995) | 93,107 | (135,533) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 131,783 | 32.870% | 99,182 | 252,258 | 196,028 | 9,624 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (840,910) | -34.427% | (1,282,398) | (2,281,624) | (2,386,067) | (718,557) | |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 42,887 | 455.387% | 7,722 | (70,420) | (31,648) | (9,146) |
| Depreciation & Amortisation | 323,797 | -1.447% | 328,552 | 303,220 | 263,907 | 262,559 |
| Directors' Emoluments | -- | -- | 40,585 | 55,345 | 68,691 | 102,780 |
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | -84.000 | -35.385% | -130.000 | -232.000 | -260.000 | -80.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (1.465) | (2.045) | (1.935) | (0.719) |
| NBV per share ($) | 5.895 | -- | 5.969 | 7.275 | 9.667 | 8.741 |
| Remarks: | Real time quote last updated: 20/03/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -840,910 |
| %Change | -34.427% |
| EPS / (LPS) | RMB -0.840 |
| NBV Per Share (¥) | RMB 5.895 |